Digital technologies - In post covid world, will it or will it not
Digital technologies are being leveraged significantly for patient-to-doctor connect currently since a face-to-face consultation may not be possible due to COVID-19. It remains to be seen if this trend will continue in the post COVID-19 period also.
Increasing overall market size but pricing pressure might continue
Pharmaceutical spending in the top five Western European (WE5) markets is projected to grow at about 3-6% CAGR to US$210-240 Billion by 2024. Launch of new-age specialty products will drive this growth. Government led price control initiatives to improve patient access is likely to act as a counter-balancing force to this growth.
Indian pharma industry has some inherent strength
India is uniquely positioned as a crucial supplier of pharmaceuticals by way of chemistry expertise, lower personnel costs and the ability to manufacture quality medicines in compliance with global regulatory standards. It will continue to be an important player in the global generics market.
Sun Pharmaceutical Industries Share Price
- Open1,520.00
- High1,538.95
- Low1,515.60
- Prev Close1,516.25
- Volume26,34,599
- VWAP(₹)1,525.23
Sun Pharma share price insights
Dividend Announcement
Company announced a dividend of Rs 5.0 per share on 22 May, 2024 with record date of 12 Jul, 2024.ROE Outperforming 5 Year Average
Company delivered ROE of 15.04% in year ending 31 Mar, 2024 outperforming its 5 year avg. of 10.79%. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)Stock Returns vs Nifty 100
Stock gave a 3 year return of 126.03% as compared to Nifty 100 which gave a return of 52.57%. (as of last trading session)Sun Pharma Share Price Update
Sun Pharmaceutical Industries Ltd. share price moved up by 0.31% from its previous close of Rs 1,516.25. Sun Pharmaceutical Industries Ltd. stock last traded price is 1,520.85
Share Price Value Today/Current/Last 1,520.85 Previous Day 1,516.25
Sun Pharma Share Price Returns
| 1 Day | 0.31% |
| 1 Month | 3.82% |
| 3 Months | -6.15% |
| 1 Year | 48.84% |
| 3 Years | 124.88% |
| 5 Years | 279.31% |
Key Metrics
| PE Ratio(x) | 38.33 |
| EPS - TTM(₹) | 39.91 |
| MCap(₹ Cr.) | 3,67,050 |
| MCap Rank | 1 |
| PB Ratio(x) | 5.42 |
| Div Yield(%) | 0.88 |
| Face Value(₹) | 1.00 |
| 52W High(₹) | 1,638.85 |
| 52W Low(₹) | 995.00 |
| MCap/Sales | 8.02 |
| Beta(1 Month) | 0.00 |
| BV/Share(₹) | 279.69 |
Sun Pharma Share Recommendations
30 Analysts
SellSellHoldBuyStrong
Buy
| Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 14 |
| Buy | 12 | 12 | 12 | 11 |
| Hold | 7 | 7 | 7 | 5 |
| Sell | 2 | 2 | 2 | 1 |
| Strong Sell | - | - | - | - |
| # Analysts | 30 | 30 | 30 | 31 |
Sun Pharma News & Analysis
NewsAuto & FMCG stocks offer support as Sensex settles 131 points higher; Nifty tops 23,500
NewsMonday blues! Heavyweights drag Sensex 400 points lower; Nifty below 23,400
NewsBulls Charge Ahead: Investors reap over ₹1 L cr as Sensex, Nifty hit new highs Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requiremen..
Announcements
Sun Pharma Financials
Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Total Income 12,588.84 12,630.90 12,486.02 12,145.28 11,303.95 Total Income Growth (%) -0.33 1.16 2.81 7.44 -0.97 Total Expenses 9,699.75 9,595.82 9,645.85 9,583.26 8,971.52 Total Expenses Growth (%) 1.08 -0.52 0.65 6.82 0.84 EBIT 2,889.09 3,035.08 2,840.17 2,562.02 2,332.43 EBIT Growth (%) -4.81 6.86 10.86 9.84 -7.36 Profit after Tax (PAT) 2,654.58 2,523.75 2,375.51 2,022.54 1,984.47 PAT Growth (%) 5.18 6.24 17.45 1.92 -8.38 EBIT Margin (%) 22.95 24.03 22.75 21.09 20.63 Net Profit Margin (%) 21.09 19.98 19.03 16.65 17.56 Basic EPS (₹) 11.10 10.50 9.90 8.40 8.30 All figures in Rs Cr, unless mentioned otherwise
InsightsEmployee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 19.44% towards employee cost in the year ending 31 Mar, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 85,462.88 80,743.59 69,799.87 67,666.73 68,252.46 Total Assets Growth (%) 5.84 15.68 3.15 -0.86 5.50 Total Liabilities 18,356.91 21,428.12 18,733.76 18,186.90 19,127.77 Total Liabilities Growth (%) -14.33 14.38 3.01 -4.92 -4.22 Total Equity 67,105.97 59,315.47 51,066.11 49,479.83 49,124.69 Total Equity Growth (%) 13.13 16.15 3.21 0.72 9.84 Current Ratio (x) 2.56 2.00 2.04 1.89 2.02 Total Debt to Equity (x) 0.04 0.11 0.02 0.07 0.17 Contingent Liabilities 0.00 7,903.07 6,756.55 7,057.73 7,508.95 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 12,134.98 4,959.33 8,984.54 6,170.37 6,554.77 Net Cash used in Investing Activities -690.20 -7,943.68 -5,724.74 536.22 -2,588.84 Net Cash flow from Financing Activities -6,710.16 2,376.07 -5,193.46 -5,980.48 -5,715.14 Net Cash Flow 4,661.92 115.48 -1,764.78 596.42 -1,385.69 Closing Cash & Cash Equivalent 9,285.65 4,623.73 4,508.25 6,273.03 5,676.61 Closing Cash & Cash Equivalent Growth (%) 100.83 2.56 -28.13 10.51 -19.62 Total Debt/ CFO (x) 0.23 1.25 0.10 0.54 1.16 All figures in Rs Cr, unless mentioned otherwise
InsightsDecrease in Cash from Investing
Company has used Rs 690.2 cr for investing activities which is an YoY decrease of 91.31%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 15.04 15.13 6.81 6.24 8.31 Return on Capital Employed (%) 17.26 16.02 17.44 14.06 10.60 Return on Assets (%) 11.20 10.49 4.68 4.29 5.51 Interest Coverage Ratio (x) 60.29 71.40 88.88 65.95 25.19 Asset Turnover Ratio (x) 0.58 0.58 0.56 0.49 0.49 Price to Earnings (x) 40.65 27.86 67.11 49.50 22.47 Price to Book (x) 6.11 4.21 4.57 3.09 1.87 EV/EBITDA (x) 26.75 19.51 19.30 15.36 11.73 EBITDA Margin (%) 29.64 27.98 29.28 27.84 23.22 InsightsROE Outperforming 5 Year Average
Company delivered ROE of 15.04% in year ending 31 Mar, 2024 outperforming its 5 year avg. of 10.79%. (Source: Consolidated Financials)
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Sun Pharma Stock Performance 0.31 4.18 1.75 -5.28 54.57 126.03 280.93 Divis Labs Stock Performance 1.64 6.72 21.28 27.62 34.06 7.71 193.47 Cipla Stock Performance -0.01 2.32 8.98 -0.16 52.78 54.47 169.48 Cadila Healthcare Stock Performance 1.61 7.38 10.92 9.95 111.51 68.79 342.50 Dr. Reddys Stock Performance 2.67 10.54 8.93 1.24 37.19 22.58 148.09 All values in %
Stock Returns vs Nifty 100
Stock gave a 3 year return of 126.03% as compared to Nifty 100 which gave a return of 52.57%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 126.03% return as compared to Nifty Pharma which gave investors 38.67% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
MF Ownership as on 31 May 2024
2,323.59
Amount Invested (in Cr.)
5.45%
% of AUM
2.57
% Change (MoM basis)
1,480.23
Amount Invested (in Cr.)
4.21%
% of AUM
20.62
% Change (MoM basis)
1,395.79
Amount Invested (in Cr.)
2.52%
% of AUM
5.72
% Change (MoM basis)
Sun Pharma Futures & Options
Corporate Actions
Final
500%
May 22, 2024
Board Meeting
Audited Results & Final Dividend
May 13, 2024
Board Meeting
Quarterly Results & Interim Dividend
Jan 15, 2024
Announced on Meeting on May 13, 2024 May 22, 2024 Audited Results & Final Dividend Jan 15, 2024 Jan 31, 2024 Quarterly Results & Interim Dividend Oct 13, 2023 Nov 01, 2023 Quarterly Results Jul 11, 2023 Aug 03, 2023 Quarterly Results May 11, 2023 May 26, 2023 Audited Results & Final Dividend Announced on Ex-Date Dividend% May 22, 2024 Jul 12, 2024 500% Jan 15, 2024 Feb 09, 2024 850% Jul 07, 2023 Jul 28, 2023 400% Jan 16, 2023 Feb 08, 2023 750% May 31, 2022 Aug 19, 2022 300% Announced on Ex-Date May 28, 2013 Jul 29, 2013 Bonus Ratio: 1 share(s) for every 1 shares held Apr 21, 2004 May 27, 2004 Bonus Ratio: 1 share(s) for every 1 shares held Feb 09, 2000 Mar 06, 2000 Bonus Ratio: 2 share(s) for every 1 shares held Announced on Ex-Date Sep 24, 2010 Nov 25, 2010 Split: Old FV5.0| New FV:1.0 Oct 28, 2002 Jan 13, 2003 Split: Old FV10.0| New FV:5.0 No Data Available
Announced on Meeting on Jul 07, 2023 Aug 28, 2023 - Aug 03, 2022 Aug 29, 2022 - Aug 04, 2021 Aug 31, 2021 Book closure from 25 Aug, 2021 to 31 Aug, 2021 Feb 05, 2021 Mar 16, 2021 - Jul 29, 2020 - Book closure from 21 Aug, 2020 to 27 Aug, 2020
About
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 364,902.86 Crore) operating in Pharmaceuticals sector.
Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023.
For the quarter ended 31-03-2024, the company has reported a Consolidated Total Income of Rs 12,588.84 Crore, down .33 % from last quarter Total Income of Rs 12,630.90 Crore and up 11.37 % from last year same quarter Total Income of Rs 11,303.95 Crore. Company has reported net profit after tax of Rs 2,666.59 Crore in latest quarter.
The company’s top management includes Mr.Dilip S Shanghvi, Mr.Abhay Gandhi, Mr.Kirti Ganorkar, Mr.S Damodharan, Dr.Uday Baldota, Mr.Aalok D Shanghvi, Mr.Sailesh T Desai, Mr.Sudhir V Valia, Mr.Gautam Doshi, Dr.Pawan Goenka, Mr.Rama Bijapurkar, Mr.Rolf Hoffmann, Mr.Sanjay Asher, Mr.C S Muralidharan, Mr.Anoop Deshpande. Company has S R B C & Co. LLP as its auditors. As on 31-03-2024, the company has a total of 239.93 Crore shares outstanding.
About Sun Pharma
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 364,902.86 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical Industries Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2023.For the quarter ended 31-03-2024, the company has reported a Consolidated Total Income of Rs 12,588.84 Crore, down .33 % from last quarter Total Income of Rs 12,630.90 Crore and up 11.37 % from last year same quarter Total Income of Rs 11,303.95 Crore. Company has reported net profit after tax of Rs 2,666.59 Crore in latest quarter.The company’s top management includes Mr.Dilip S Shanghvi, Mr.Abhay Gandhi, Mr.Kirti Ganorkar, Mr.S Damodharan, Dr.Uday Baldota, Mr.Aalok D Shanghvi, Mr.Sailesh T Desai, Mr.Sudhir V Valia, Mr.Gautam Doshi, Dr.Pawan Goenka, Mr.Rama Bijapurkar, Mr.Rolf Hoffmann, Mr.Sanjay Asher, Mr.C S Muralidharan, Mr.Anoop Deshpande. Company has S R B C & Co. LLP as its auditors. As on 31-03-2024, the company has a total of 239.93 Crore shares outstanding.
Industry
Key Indices Listed On
Nifty 50, BSE Sensex, Nifty 100, Nifty 200, Nifty 500
Address
Sun Pharma Advanced Research Centre (SPARC),Tandalja,Vadodra, Gujarat - 390012
Executive Leadership
Dilip S Shanghvi
Managing DirectorAbhay Gandhi
CEO - North AmericaKirti Ganorkar
CEO - India BusinessS Damodharan
CEO - API BusinessAuditors
FAQs about Sun Pharma share
- 1. What's Sun Pharma share price today and what are Sun Pharma share returns ?Sun Pharma share price was Rs 1,520.85 as on 28 Jun, 2024, 03:58 PM IST. Sun Pharma share price was up by 0.31% based on previous share price of Rs 1,521.15. Sun Pharma share price trend:
- Last 1 Month: Sun Pharma share price moved up by 3.82%
- Last 3 Months: Sun Pharma share price moved down by 6.15%
- Last 12 Months: Sun Pharma share price moved up 48.84%
- Last 3 Years: Sun Pharma Share price moved up by 124.88%
- 2. What are the key metrics to analyse Sun Pharma Share Price?Sun Pharma share can be quickly analyzed on following metrics:
- Stock's PE is 38.33
- Price to Book Ratio of 5.42
- 3. What is the market cap of Sun Pharma?Within the Pharmaceuticals sector, Sun Pharma stock has a market cap rank of 1. Sun Pharma has a market cap of Rs 3,67,050 Cr.
- 4. Who are the key owners of Sun Pharma stock?
- Promoter holding has not changed in last 9 months and holds 54.48 stake as on 31 Mar 2024
- Domestic Institutional Investors holding have gone down from 19.5 (30 Jun 2023) to 18.65 (31 Mar 2024)
- Foreign Institutional Investors holding has gone up from 16.48 (30 Jun 2023) to 17.72 (31 Mar 2024)
- Other investor holding have gone down from 9.54 (30 Jun 2023) to 9.15 (31 Mar 2024)
- 5. What are the returns for Sun Pharma share?Return Performance of Sun Pharma Shares:
- 1 Week: Sun Pharma share price moved up by 3.65%
- 1 Month: Sun Pharma share price moved up by 3.82%
- 3 Month: Sun Pharma share price moved down by 6.15%
- 6 Month: Sun Pharma share price moved up by 20.50%
- 6. What is the CAGR of Sun Pharma?The CAGR of Sun Pharma is 9.69.
- 7. Which are the key peers to Sun Pharma?Top 10 Peers for Sun Pharma are Divi's Laboratories Ltd., Cipla Ltd., Zydus Lifesciences Ltd., Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd. and Biocon Ltd.
- 8. What has been highest price of Sun Pharma share in last 52 weeks?In last 52 weeks Sun Pharma share had a high price of Rs 1,638.85 and low price of Rs 995.00
- 9. Who is the Chief Executive Officer of Sun Pharma?Abhay Gandhi is the CEO - North America of Sun Pharma
- 10. What are the Sun Pharma quarterly results?Total Revenue and Earning for Sun Pharma for the year ending 2024-03-31 was Rs 49851.04 Cr and Rs 9576.38 Cr on Consolidated basis. Last Quarter 2024-03-31, Sun Pharma reported an income of Rs 12588.84 Cr and profit of Rs 2654.58 Cr.
- 11. What is the PE & PB ratio of Sun Pharma?The PE ratio of Sun Pharma stands at 37.99, while the PB ratio is 5.42.
- 12. What dividend is Sun Pharma giving?An equity Final dividend of Rs 5 per share was declared by Sun Pharmaceutical Industries Ltd. on 22 May 2024. So, company has declared a dividend of 500% on face value of Rs 1 per share. The ex dividend date is 12 Jul 2024.
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.